Exelixis (EXEL) is back in focus after reporting fourth quarter earnings that topped market expectations, along with full-year results and fresh progress on its oncology pipeline, including an FDA review for zanzalintinib.

At a share price of US$42.98, Exelixis has seen a modest 7 day share price return of 0.92% and a 1 month share price return decline of 2.41%. Its 1 year total shareholder return of 31.0% and 3 year total shareholder return of about 14x indicate stronger performance over a longer period as investors react to solid earnings and pipeline updates such as the zanzalintinib NDA.

If this FDA news has you thinking more broadly about oncology and biotech, it could be a good moment to scan 27 healthcare AI stocks as potential additions to your watchlist.

With earnings ahead of expectations, a pipeline anchored by zanzalintinib, and the stock trading near but not at analyst targets, the key question now is whether Exelixis is still offering upside or if the market is already pricing in future growth.

Most Popular Narrative: 6.2% Undervalued

Exelixis is trading at US$42.98 versus a widely followed fair value estimate of US$45.83, and that gap is tied closely to the zanzalintinib story.

The company's substantial free cash flow, strong balance sheet, and disciplined capital allocation (including aggressive share repurchases and prioritization of high-probability, high-value R&D programs) position Exelixis to invest in next-generation discovery and strategic partnerships, which has the potential to improve operating leverage and net margins over time as the product portfolio scales.

Curious what supports that fair value uplift? The narrative leans on double digit top line expansion, rising profitability, and a compressed future earnings multiple that contrasts with many peers.

Result: Fair Value of $45.83 (UNDERVALUED)

However, the heavy reliance on CABOMETYX and the growing share of discounted 340B volume mean pricing, competition, or patent shifts could quickly challenge that underpriced story.

Build Your Own Exelixis Narrative

If parts of this story do not sit right with you, or you would rather lean on your own work, you can build a full view in just a few minutes, starting with Do it your way.

A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Exelixis is on your radar, do not stop there. Broaden your watchlist now so you are not sidelined when other opportunities emerge.

• Zero in on value by using 51 high quality undervalued stocks to spot companies where quality fundamentals meet prices that may not fully reflect them.
• Prioritize resilience and scan 83 resilient stocks with low risk scores to find businesses with lower overall risk scores that could help steady your portfolio.
• Hunt for potential standouts by working through our screener containing 24 high quality undiscovered gems to surface lesser known names with strong underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.